常规使用滑液α-防御素并非必要
该研究纳入158例疑似假体周围感染(PJI)患者,由四位医师在盲法下分别根据传统检测数据及附加滑液α-防御素结果进行随机化判读。结果显示,在传统检测已能明确诊断或排除PJI时,附加α-防御素并未改善诊断能力;仅在传统术前检测无法确定时,α-防御素有助于诊断或排除PJI。因此不建议常规使用α-防御素,仅建议在传统检测结果不确定时使用。
要点
- 在传统检测已明确PJI诊断时,附加α-防御素未改变诊断(术前OR 0.52,95%CI 0.14-1.88;术中OR 0.52,95%CI 0.18-1.55)。
- 在传统术前检测无法确定时,α-防御素有助于诊断(OR 0.44,95%CI 0.30-0.64)或排除(OR 0.41,95%CI 0.17-0.98)PJI。
- 27例传统检测无法确定者中,24例(89%)从附加α-防御素检测中获益。
核心结论
- 实验室滑液α-防御素免疫分析在传统血清学和滑液分析基础上,并未改善PJI的诊断或排除,除非诊断不明确。
- 不建议常规使用α-防御素,仅建议在传统检测结果不确定时使用。
研究设计与样本
- 连续纳入158例接受PJI评估的患者,其中94例接受了翻修关节置换术。
- 四位医师根据2014年MSIS标准,在盲法下分别对传统检测数据及附加α-防御素结果进行随机化判读。
主要发现
- 附加α-防御素结果后,观察者内信度和观察者间一致性未发生变化。
- α-防御素阳性者滑液WBC均值31,854 cells/μL(SD 32,594),%PMN均值93.0%(SD 5.5%),均高于阴性者(WBC均值974 cells/μL,SD 3,988;%PMN均值39.4%,SD 28.6%;两者p<0.001)。
- 附加α-防御素结果未改变基于术前数据(OR 0.52,95%CI 0.14-1.88;p=0.315)或术中数据(OR 0.52,95%CI 0.18-1.55;p=0.242)的PJI诊断。
- 在传统术前检测无法确定时,α-防御素有助于诊断(OR 0.44,95%CI 0.30-0.64;p<0.001)或排除(OR 0.41,95%CI 0.17-0.98;p=0.044)PJI。
- 27例传统检测无法确定者中,24例(89%)从附加α-防御素检测中获益。
关键数值与推荐
- PJI诊断依据2014年MSIS标准,判读结果为是、否或不确定。
临床怎么用
- 不推荐将滑液α-防御素作为PJI的常规检测项目。
- 仅在传统血清学和滑液分析结果无法确定PJI诊断时,考虑附加α-防御素检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To establish the utility of adding the laboratory-based synovial alpha-defensin immunoassay to the traditional diagnostic work-up of a prosthetic joint infection (PJI). METHODS: A group of four physicians evaluated 158 consecutive patients who were worked up for PJI, of which 94 underwent revision arthroplasty. Each physician reviewed the diagnostic data and decided on the presence of PJI according to the 2014 Musculoskeletal Infection Society (MSIS) criteria (yes, no, or undetermined). Their initial randomized review of the available data before or after surgery was blinded to each alpha-defensin result and a subsequent randomized review was conducted with each result. Multilevel logistic regression analysis assessed the effect of having the alpha-defensin result on the ability to diagnose PJI. Alpha-defensin was correlated to the number of synovial white blood cells (WBCs) and percentage of polymorphonuclear cells (%PMN). RESULTS: Intraobserver reliability and interobserver agreement did not change when the alpha-defensin result was available. Positive alpha-defensin results had greater synovial WBCs (mean 31,854 cells/μL, SD 32,594) and %PMN (mean 93.0%, SD 5.5%) than negative alpha-defensin results (mean 974 cells/μL, SD 3,988; p < 0.001 and mean 39.4% SD 28.6%; p < 0.001). Adding the alpha-defensin result did not alter the diagnosis of a PJI using preoperative (odds ratio (OR) 0.52, 95% confidence interval (CI) 0.14 to 1.88; p = 0.315) or operative (OR 0.52, CI 0.18 to 1.55; p = 0.242) data when clinicians already decided that PJI was present or absent with traditionally available testing. However, when undetermined with traditional preoperative testing, alpha-defensin helped diagnose (OR 0.44, CI 0.30 to 0.64; p < 0.001) or rule out (OR 0.41, CI 0.17 to 0.98; p = 0.044) PJI. Of the 27 undecided cases with traditional testing, 24 (89%) benefited from the addition of alpha-defensin testing. CONCLUSION: The laboratory-based synovial alpha-defensin immunoassay did not help diagnose or rule out a PJI when added to routine serologies and synovial fluid analyses except in cases where the diagnosis of PJI was unclear. We recommend against the routine use of alpha-defensin and suggest using it only when traditional testing is indeterminate. Cite this article: Bone Joint J 2020;102-B(5):593-599.
引用
- Amanatullah DF, Cheng RZ, Huddleston Iii JI, et al. The routine use of synovial alpha-defensin is not necessary. Bone Joint J. 2020. PMID: 32349594. doi:10.1302/0301-620X.102B5.BJJ-2019-0473.R3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。